Special science segment part of Reliv International’s 25th anniversary celebration in Orlando on July 18-20
CHESTERFIELD, MO (PRWEB) June 28, 2013
Reliv International (NASDAQ: RELV) today announced that the company’s 25th anniversary conference in Orlando on July 18-20 will include a presentation on nutritional epigenetics and the science behind the soy peptide lunasin. Presenters will include Dr. Carl Hastings, Reliv chief scientific officer, and Dr. Alfredo Galvez, research scientist at the Center of Excellence in Nutritional Genomics at UC Davis and lead scientific advisor at the Missouri Plant Science Center (MPSC).
Hastings will discuss the importance of the joint biotechnology and development partnership between Reliv and the MPSC, the achievements of this partnership to date and its potential for further innovations in nutrition science.
Galvez will present the latest lunasin research, describe the emergence of epigenetics as a new frontier in our understanding of human health and discuss the potential applications for nutritional epigenetics in the future of health care.
Lunasin and Epigenetics
Epigenetics is the study of changes in gene expression in cells caused by mechanisms other than changes in DNA. The epigenome, which literally means “beyond the genome,” is a higher level of complexity in the cell that determines which genes are used, when they are used and how much they are used. The epigenome is the reason why different types of cells — eye cells, skin cells, liver cells — can have the same DNA but perform vastly different functions.
Lunasin is the first nutritional compound identified to promote optimal cellular health through an epigenetic mechanism of action. Lunasin attaches itself to the epigenome in the cell to increase expression of important genes needed for normal cell functioning and protect the cells from environmental damage once it occurs. Learn more about lunasin and epigenetics.
LunaRich from Reliv
LunaRich® is a nutritional ingredient available in Reliv products that optimizes bioactive lunasin. LunaRich is made from non-GMO soybean varieties with the highest concentration of lunasin and manufactured through a proprietary mechanical process (vs. chemical) that maintains the lunasin’s bioactivity.
“No other company is advancing the field of nutritional epigenetics like Reliv,” said Galvez. “We are in the middle of a revolution in nutrition and we are all witnesses.”
About Reliv International, Inc.
Reliv International, based in Chesterfield, Mo., produces nutritional supplements that promote optimal nutrition along with premium skincare products. Reliv supplements address essential nutrition, weight loss, athletic performance, digestive health, women's health, anti-aging and healthy energy. Reliv is the exclusive provider of LunaRich® products, which optimize levels of lunasin, the peptide behind many of soy’s health benefits. The company sells its products through an international network marketing system of independent distributors in 16 countries. Learn more about Reliv at http://www.reliv.com, or on Facebook, Twitter or YouTube. Reported by PRWeb 15 hours ago.
CHESTERFIELD, MO (PRWEB) June 28, 2013
Reliv International (NASDAQ: RELV) today announced that the company’s 25th anniversary conference in Orlando on July 18-20 will include a presentation on nutritional epigenetics and the science behind the soy peptide lunasin. Presenters will include Dr. Carl Hastings, Reliv chief scientific officer, and Dr. Alfredo Galvez, research scientist at the Center of Excellence in Nutritional Genomics at UC Davis and lead scientific advisor at the Missouri Plant Science Center (MPSC).
Hastings will discuss the importance of the joint biotechnology and development partnership between Reliv and the MPSC, the achievements of this partnership to date and its potential for further innovations in nutrition science.
Galvez will present the latest lunasin research, describe the emergence of epigenetics as a new frontier in our understanding of human health and discuss the potential applications for nutritional epigenetics in the future of health care.
Lunasin and Epigenetics
Epigenetics is the study of changes in gene expression in cells caused by mechanisms other than changes in DNA. The epigenome, which literally means “beyond the genome,” is a higher level of complexity in the cell that determines which genes are used, when they are used and how much they are used. The epigenome is the reason why different types of cells — eye cells, skin cells, liver cells — can have the same DNA but perform vastly different functions.
Lunasin is the first nutritional compound identified to promote optimal cellular health through an epigenetic mechanism of action. Lunasin attaches itself to the epigenome in the cell to increase expression of important genes needed for normal cell functioning and protect the cells from environmental damage once it occurs. Learn more about lunasin and epigenetics.
LunaRich from Reliv
LunaRich® is a nutritional ingredient available in Reliv products that optimizes bioactive lunasin. LunaRich is made from non-GMO soybean varieties with the highest concentration of lunasin and manufactured through a proprietary mechanical process (vs. chemical) that maintains the lunasin’s bioactivity.
“No other company is advancing the field of nutritional epigenetics like Reliv,” said Galvez. “We are in the middle of a revolution in nutrition and we are all witnesses.”
About Reliv International, Inc.
Reliv International, based in Chesterfield, Mo., produces nutritional supplements that promote optimal nutrition along with premium skincare products. Reliv supplements address essential nutrition, weight loss, athletic performance, digestive health, women's health, anti-aging and healthy energy. Reliv is the exclusive provider of LunaRich® products, which optimize levels of lunasin, the peptide behind many of soy’s health benefits. The company sells its products through an international network marketing system of independent distributors in 16 countries. Learn more about Reliv at http://www.reliv.com, or on Facebook, Twitter or YouTube. Reported by PRWeb 15 hours ago.